NCNA has been the topic of a number of other reports. Zacks Investment Research upgraded shares of NuCana from a sell rating to a hold rating in a research note on Tuesday, July 23rd. William Blair reiterated an outperform rating on shares of NuCana in a research note on Thursday, May 16th. Finally, BidaskClub upgraded shares of NuCana from a strong sell rating to a sell rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. NuCana presently has a consensus rating of Buy and an average price target of $25.50.
Shares of NCNA stock traded down $0.13 on Thursday, hitting $8.65. The stock had a trading volume of 13,585 shares, compared to its average volume of 13,289. The stock has a market capitalization of $277.47 million, a price-to-earnings ratio of -15.18 and a beta of 3.27. The business has a 50 day simple moving average of $10.02. NuCana has a 52-week low of $7.53 and a 52-week high of $30.10.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Marshall Wace North America L.P. boosted its stake in NuCana by 558.8% during the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after acquiring an additional 51,607 shares during the last quarter. Rothschild Investment Corp IL bought a new position in NuCana during the 1st quarter valued at $211,000. Aperio Group LLC bought a new position in shares of NuCana in the 2nd quarter worth about $39,000. Asymmetry Capital Management L.P. lifted its position in shares of NuCana by 5.4% in the 1st quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock worth $772,000 after buying an additional 2,346 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in shares of NuCana by 5.6% in the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock worth $1,323,000 after buying an additional 4,160 shares during the last quarter. Hedge funds and other institutional investors own 38.08% of the company’s stock.
NuCana Company Profile
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.
Further Reading: Percentage Decliners
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.